Engraftment data
| . | Tt-BuCy . | ATG-BuCy . | P . |
|---|---|---|---|
| No. of patients | 30 | 51 | |
| Cell dose, 108 nucleated cells/kg* | 5.4 (3.1-16.8) | 5.5 (2.6-18.9) | .587 |
| G-CSF marrow priming (5 µg/kg × 3-5 d) | 0 | 32 of 51 (63%) | <.001 |
| Days to ANC >500/µL* | 15 (12-28) | 18 (13-32) | <.001 |
| Total days of neutropenia <500/µL* | 14 (10-27) | 15 (8-28) | .092 |
| Days to ANC >200/µL* | 12 (10-28) | 16 (11-29) | <.001 |
| Total days of neutropenia <200/µL* | 11 (8-27) | 12 (6-24) | .489 |
| Use of G-CSF post-BMT | 2 (7%) | 7 (14%) | .473 |
| Days to platelet count >20 000/µL* | 20 (13-68) | 21 (13-38) | .429 |
| Total red cell transfusions* | 2 (0-9) | 3 (0 to 9) | .2392 |
| Last day of red cell transfusion* | 11 (−14 to 152) | 12 (−3 to 58) | .643 |
| Total platelet transfusions* | 4 (0-19) | 4 (0-28) | .945 |
| Discharge day* | 39 (21-165) | 46 (23-99) | .235 |
| . | Tt-BuCy . | ATG-BuCy . | P . |
|---|---|---|---|
| No. of patients | 30 | 51 | |
| Cell dose, 108 nucleated cells/kg* | 5.4 (3.1-16.8) | 5.5 (2.6-18.9) | .587 |
| G-CSF marrow priming (5 µg/kg × 3-5 d) | 0 | 32 of 51 (63%) | <.001 |
| Days to ANC >500/µL* | 15 (12-28) | 18 (13-32) | <.001 |
| Total days of neutropenia <500/µL* | 14 (10-27) | 15 (8-28) | .092 |
| Days to ANC >200/µL* | 12 (10-28) | 16 (11-29) | <.001 |
| Total days of neutropenia <200/µL* | 11 (8-27) | 12 (6-24) | .489 |
| Use of G-CSF post-BMT | 2 (7%) | 7 (14%) | .473 |
| Days to platelet count >20 000/µL* | 20 (13-68) | 21 (13-38) | .429 |
| Total red cell transfusions* | 2 (0-9) | 3 (0 to 9) | .2392 |
| Last day of red cell transfusion* | 11 (−14 to 152) | 12 (−3 to 58) | .643 |
| Total platelet transfusions* | 4 (0-19) | 4 (0-28) | .945 |
| Discharge day* | 39 (21-165) | 46 (23-99) | .235 |
Bold type indicates statistical significance.
Median (range).